Assetmark Inc. Raises Stake in Axon Enterprise, Inc $AXON

Assetmark Inc. boosted its position in Axon Enterprise, Inc (NASDAQ:AXON) by 13.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,747 shares of the biotechnology company’s stock after buying an additional 1,126 shares during the period. Assetmark Inc.’s holdings in Axon Enterprise were worth $8,070,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of AXON. Brighton Jones LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at approximately $480,000. DAVENPORT & Co LLC boosted its position in Axon Enterprise by 5.1% in the 1st quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company’s stock worth $494,000 after purchasing an additional 46 shares in the last quarter. First Horizon Advisors Inc. boosted its position in Axon Enterprise by 8.2% in the 1st quarter. First Horizon Advisors Inc. now owns 620 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 47 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Axon Enterprise by 1,475.1% in the 1st quarter. Teacher Retirement System of Texas now owns 10,585 shares of the biotechnology company’s stock worth $5,567,000 after purchasing an additional 9,913 shares in the last quarter. Finally, IFM Investors Pty Ltd boosted its position in Axon Enterprise by 3.3% in the 1st quarter. IFM Investors Pty Ltd now owns 14,795 shares of the biotechnology company’s stock worth $7,781,000 after purchasing an additional 479 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In other news, Director Hadi Partovi acquired 1,358 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 13th. The stock was purchased at an average cost of $740.00 per share, with a total value of $1,004,920.00. Following the purchase, the director owned 237,938 shares in the company, valued at $176,074,120. This trade represents a 0.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $750.10, for a total value of $5,919,039.10. Following the completion of the transaction, the insider directly owned 144,538 shares of the company’s stock, valued at approximately $108,417,953.80. This represents a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 59,932 shares of company stock worth $45,115,616 in the last quarter. 4.40% of the stock is owned by insiders.

Axon Enterprise Trading Down 0.9%

Shares of AXON stock opened at $732.23 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The company has a market cap of $57.48 billion, a price-to-earnings ratio of 180.80, a PEG ratio of 29.49 and a beta of 1.41. The stock has a 50 day simple moving average of $731.05 and a 200-day simple moving average of $733.88. Axon Enterprise, Inc has a 1-year low of $422.38 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business’s quarterly revenue was up 32.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.20 EPS. On average, equities research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXON has been the topic of several recent research reports. JPMorgan Chase & Co. upped their price objective on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday, July 17th. JMP Securities restated a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Raymond James Financial restated an “outperform” rating and issued a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, UBS Group reaffirmed a “neutral” rating and set a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.